These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19065567)

  • 1. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
    Kieran MW; Supko JG; Wallace D; Fruscio R; Poussaint TY; Phillips P; Pollack I; Packer R; Boyett JM; Blaney S; Banerjee A; Geyer R; Friedman H; Goldman S; Kun LE; Macdonald T;
    Pediatr Blood Cancer; 2009 Feb; 52(2):169-76. PubMed ID: 19065567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S; Laird D; Cherrington JM; Knox SJ
    Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
    Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
    Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
    Kieran MW; Chi S; Goldman S; Onar-Thomas A; Poussaint TY; Vajapeyam S; Fahey F; Wu S; Turner DC; Stewart CF; Moses M; Packer RJ; Jakacki R; Banerjee A; Boyett JM; Fouladi M; Kun L
    Childs Nerv Syst; 2015 Sep; 31(9):1433-45. PubMed ID: 26188774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
    O'Donnell A; Padhani A; Hayes C; Kakkar AJ; Leach M; Trigo JM; Scurr M; Raynaud F; Phillips S; Aherne W; Hardcastle A; Workman P; Hannah A; Judson I
    Br J Cancer; 2005 Oct; 93(8):876-83. PubMed ID: 16222321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
    Cooney MM; Tserng KY; Makar V; McPeak RJ; Ingalls ST; Dowlati A; Overmoyer B; McCrae K; Ksenich P; Lavertu P; Ivy P; Hoppel CL; Remick S
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):295-300. PubMed ID: 15538570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
    Salzberg M; Pless M; Rochlitz C; Ambrus K; Scigalla P; Herrmann R
    Invest New Drugs; 2006 Jul; 24(4):299-304. PubMed ID: 16237511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
    Hoff PM; Wolff RA; Bogaard K; Waldrum S; Abbruzzese JL
    Jpn J Clin Oncol; 2006 Feb; 36(2):100-3. PubMed ID: 16449240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
    Giles FJ; Stopeck AT; Silverman LR; Lancet JE; Cooper MA; Hannah AL; Cherrington JM; O'Farrell AM; Yuen HA; Louie SG; Hong W; Cortes JE; Verstovsek S; Albitar M; O'Brien SM; Kantarjian HM; Karp JE
    Blood; 2003 Aug; 102(3):795-801. PubMed ID: 12649163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
    Martin LK; Bekaii-Saab T; Serna D; Monk P; Clinton SK; Grever MR; Kraut EH
    Onkologie; 2013; 36(11):657-60. PubMed ID: 24192770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
    Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
    Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
    Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
    J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
    Zangari M; Anaissie E; Stopeck A; Morimoto A; Tan N; Lancet J; Cooper M; Hannah A; Garcia-Manero G; Faderl S; Kantarjian H; Cherrington J; Albitar M; Giles FJ
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):88-95. PubMed ID: 14734456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
    Stadler WM; Cao D; Vogelzang NJ; Ryan CW; Hoving K; Wright R; Karrison T; Vokes EE
    Clin Cancer Res; 2004 May; 10(10):3365-70. PubMed ID: 15161690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
    Lockhart AC; Cropp GF; Berlin JD; Donnelly E; Schumaker RD; Schaaf LJ; Hande KR; Fleischer AC; Hannah AL; Rothenberg ML
    Am J Clin Oncol; 2006 Apr; 29(2):109-15. PubMed ID: 16601426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.